Answers are grounded in this paper and cite their sources.
Explores the role of concurrent TP53 and TERT promoter mutations in bladder cancer, suggesting a significant impact on survival outcomes.
Background Mutations in the TP53 gene and telomerase reverse transcriptase promoter ( TERT p) are among the most frequent genetic alterations in bladder cancer, but the clinical impact of their co-occurrence has not been fully explored. In this study, we assessed the mutational landscape as well as the prognostic significance of concurrent TERT p and TP53 mutations in a cohort of bladder urothelial carcinoma patients. Methods Using data from the cBioPortal database, we retrospectively analysed primary bladder urothelial carcinoma cases profiled with the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assays. We investigated the relationships between tumour mutational burden (TMB), microsatellite instability (MSI), and somatic mutations. The Kaplan-Meier method was used to calculate patient overall survival. Log-rank testing and multivariable Cox proportional hazards modelling were used to evaluate prognostic factors. Results Among the 1,111 cancer cases, 416 exhibited concurrent mutations in both TERT p and TP53 , 387 harboured mutations exclusively in TERT p, 132 showed mutations only in the TP53 gene, and 176 cases were double wild-type for both genetic regions (wt/wt). Overall survival was significantly longer in the wt/wt group compared to TERT p (HR 1.83, 95% CI 1.27 - 2.62, P<0.001), to TP53 mutant alone (HR 1.84, 95% CI 1.19 - 2.85, P = 0.006) and to TERT p/ TP53 (HR 2.32, 95% CI 1.63 – 3.31, P<0.001) mutant groups. The presence of TERT p and TP53 mutations was associated with higher tumour mutational burden (TMB ≥10 mutations/Mb) and increased microsatellite instability (MSI) scores (P < 0.001). The significant association between TERT p and TP53 mutations was independently validated in a separate cohort. Conclusions Bladder urothelial cancer can be stratified into biologically and clinically distinct subtypes on the basis of cancer driver mutations, with concomitant TERT p/ TP53 nucleotide changes strongly linked to reduced patients’ overall survival. These results suggest a potential cooperative interaction between mutant TERT p and TP53 in the pathogenesis of bladder cancer, highlighting their significance as prognostic biomarkers and promising targets for novel therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Tornesello et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: